title: Improvement of learning and increase in dopamine level in the frontal cortex by methylphenidate in mice lacking dopamine transporter.
abstract: The symptoms of attention-deficit/hyperactivity disorder (ADHD) are characterized by inattention and hyperactivity-impulsivity. It is a common childhood neurodevelopmental disorder that often persists into adulthood. Improvements in ADHD symptoms using psychostimulants have been recognized as a paradoxical calming effect. The psychostimulant methylphenidate (MPH) is currently used as the first-line medication for the management of ADHD. Recent studies have drawn attention to altered dopamine-mediated neurotransmission in ADHD, particularly reuptake by the dopamine transporter (DAT). This hypothesis is supported by the observation that DAT knockout mice exhibit marked hyperactivity that is responsive to acute MPH treatment. However, other behaviors relevant to ADHD have not been fully clarified. In the present study, we observed learning impairment in shuttle-box avoidance behavior together with hyperactivity in a novel environment in DAT knockout mice. Methylphenidate normalized these behaviors and enhanced escape activity in the tail suspension test. Interestingly, the effective dose of MPH increased extracellular dopamine in the prefrontal cortex but not striatum, suggesting an important role for changes in prefrontal dopamine in ADHD. Research that uses rodent models such as DAT knockout mice may be useful for elucidating the pathophysiology of ADHD.
authors.forename: Y
authors.initials: Y
authors.lastname: Takamatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Hagino
authors.forename: A
authors.initials: A
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: S Y
authors.initials: SY
authors.lastname: Nagasawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kubo
authors.forename: M
authors.initials: M
authors.lastname: Mizuguchi
authors.forename: G R
authors.initials: GR
authors.lastname: Uhl
authors.forename: I
authors.initials: I
authors.lastname: Sora
authors.affiliation: Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan. ikeda-kz@igakuken.or.jp.
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
mesh_terms: D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology; D001362:Avoidance Learning; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D008774:Methylphenidate / Q000494:pharmacology*; D057507:Mice, 129 Strain; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity; D017397:Prefrontal Cortex / Q000378:metabolism
chemical_list: D018765:Dopamine Uptake Inhibitors; D008774:Methylphenidate; D004298:Dopamine
references.citation: J Child Neurol. 1991;6 Suppl:S128-31
references.pmid: 2002211
references.citation: Behav Brain Funct. 2009 Feb 18;5:7
references.pmid: 19226460
references.citation: J Neurochem. 1990 Sep;55(3):1067-70
references.pmid: 2117046
references.citation: BMC Pharmacol. 2006 Mar 03;6:6
references.pmid: 16515684
references.citation: Science. 1999 Jan 15;283(5400):397-401
references.pmid: 9888856
references.citation: Neuroimage. 2007 Feb 1;34(3):1182-90
references.pmid: 17126039
references.citation: J Neurosci. 2002 Jan 15;22(2):389-95
references.pmid: 11784783
references.citation: Biol Psychiatry. 2011 Aug 1;70(3):255-62
references.pmid: 21664605
references.citation: Brain Res. 1984 Jun 15;303(2):319-29
references.pmid: 6430466
references.citation: J Neurosci. 1998 Apr 1;18(7):2697-708
references.pmid: 9502827
references.citation: Neuropsychopharmacology. 2004 Oct;29(10):1790-9
references.pmid: 15226739
references.citation: JAMA. 2009 Sep 9;302(10 ):1084-91
references.pmid: 19738093
references.citation: Dev Med Child Neurol. 2004 Mar;46(3):179-83
references.pmid: 14995087
references.citation: Fundam Clin Pharmacol. 1993;7(5):219-26
references.pmid: 8370568
references.citation: Psychol Med. 2006 Feb;36(2):159-65
references.pmid: 16420712
references.citation: Am J Hum Genet. 1995 Apr;56(4):993-8
references.pmid: 7717410
references.citation: J Neurochem. 2010 Jul;114(1):259-70
references.pmid: 20403082
references.citation: Brain Res. 2010 Feb 2;1312:89-100
references.pmid: 19932692
references.citation: Curr Opin Neurobiol. 1998 Apr;8(2):263-71
references.pmid: 9635212
references.citation: Neuroscience. 2004;126(1):21-9
references.pmid: 15145070
references.citation: Brain. 1996 Feb;119 ( Pt 1):191-202
references.pmid: 8624681
references.citation: Behav Brain Res. 2002 Mar 10;130(1-2):65-71
references.pmid: 11864719
references.citation: Clin Psychol Rev. 2005 Feb;25(2):183-213
references.pmid: 15642646
references.citation: Brain Res Dev Brain Res. 2000 Feb 7;119(2):251-7
references.pmid: 10675775
references.citation: Trends Neurosci. 1990 Jul;13(7):272-6
references.pmid: 1695402
references.citation: Exp Brain Res. 2000 Jul;133(1):130-8
references.pmid: 10933217
references.citation: Neurosci Lett. 1999 Apr 2;264(1-3):77-80
references.pmid: 10320018
references.citation: Eur J Pharmacol. 2000 Sep 29;405(1-3):263-75
references.pmid: 11033333
references.citation: Am J Psychiatry. 1999 Aug;156(8):1209-15
references.pmid: 10450262
references.citation: Neuropsychopharmacology. 2011 Jul;36(8):1575-86
references.pmid: 21451498
references.citation: J Neurosci. 1995 Mar;15(3 Pt 1):1714-23
references.pmid: 7534339
references.citation: Science. 1969 Jan 10;163(3863):139-49
references.pmid: 5762759
references.citation: J Neurosci. 2006 May 10;26(19):5091-7
references.pmid: 16687500
references.citation: Eur J Pharmacol. 1977 Jan 21;41(2):133-43
references.pmid: 832672
references.citation: Arch Gen Psychiatry. 2007 Aug;64(8):932-40
references.pmid: 17679638
references.citation: Pharmacol Biochem Behav. 2012 Apr;101(2):208-16
references.pmid: 22260871
references.citation: J Neurosci. 1998 Aug 1;18(15):5901-7
references.pmid: 9671677
references.citation: Mol Psychiatry. 1996 May;1(2):121-4
references.pmid: 9118321
references.citation: Ann N Y Acad Sci. 2002 Jun;965:434-9
references.pmid: 12105118
references.citation: J Neurochem. 1998 Jul;71(1):274-80
references.pmid: 9648875
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
references.pmid: 9636213
references.citation: Behav Pharmacol. 2008 Sep;19(5-6):566-74
references.pmid: 18690111
references.citation: Nature. 2012 Nov 8;491(7423):212-7
references.pmid: 23064228
references.citation: J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S
references.pmid: 11833633
references.citation: Prog Neurobiol. 2002 May;67(1):53-83
references.pmid: 12126656
references.citation: Neuropsychopharmacology. 2007 Oct;32(10):2108-16
references.pmid: 17342172
references.citation: Ann Neurol. 1985 Nov;18(5):617-9
references.pmid: 4073854
references.citation: Neurosci Biobehav Rev. 2006;30(1):1-23
references.pmid: 15935475
references.citation: Br J Pharmacol. 1973 Feb;47(2):332-8
references.pmid: 4722047
references.citation: Nature. 2013 Jan 24;493(7433):537-41
references.pmid: 23235822